Improved graft survival after renal transplantation in the United States, 1988 to 1996.

BACKGROUND The introduction of cyclosporine has resulted in improvement in the short-term outcome of renal transplantation, but its effect on the long-term survival of kidney transplants is not known. METHODS We analyzed the influence of demographic characteristics (age, sex, and race), transplant-related variables (living or cadaveric donor, panel-reactive antibody titer, extent of HLA matching, and cold-ischemia time), and post-transplantation variables (presence or absence of acute rejection, delayed graft function, and therapy with mycophenolate mofetil and tacrolimus) on graft survival for all 93,934 renal transplantations performed in the United States between 1988 and 1996. A regression analysis adjusted for these variables was used to estimate the risk of graft failure within the first year and more than one year after transplantation. RESULTS From 1988 to 1996, the one-year survival rate for grafts from living donors increased from 88.8 to 93.9 percent, and the rate for cadaveric grafts increased from 75.7 to 87.7 percent. The half-life for grafts from living donors increased steadily from 12.7 to 21.6 years, and that for cadaveric grafts increased from 7.9 to 13.8 years. After censoring of data for patients who died with functioning grafts, the half-life for grafts from living donors increased from 16.9 years to 35.9 years, and that for cadaveric grafts increased from 11.0 years to 19.5 years. The average yearly reduction in the relative hazard of graft failure after one year was 4.2 percent for all recipients (P<0.001), 0.4 percent for those who had acute rejection (P=0.57), and 6.3 percent for those who did not have acute rejection (P<0.001). CONCLUSIONS Since 1988, there has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors.

[1]  D. Stablein,et al.  Clinical correlates of chronic rejection in pediatric renal transplantation. A report of the North American Pediatric Renal Transplant Cooperative Study. , 1996, Transplantation.

[2]  J. Alexander,et al.  Causes of renal allograft loss in black vs. white transplant recipients in the cyclosporine era. , 1997, Clinical transplantation.

[3]  S. Hariharan,et al.  Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations. , 1995, Transplantation proceedings.

[4]  Joshua Miller,et al.  A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1 , 1997 .

[5]  D. Naimark,et al.  An analysis of predictors of long-term cadaveric renal allograft survival. , 1995, Clinical transplantation.

[6]  J. Alexander,et al.  EFFECT OF DONOR AGE ON OUTCOME OF KIDNEY TRANSPLANTATION: A TWO‐YEAR ANALYSIS OF TRANSPLANTS REPORTED TO THE UNITED NETWORK FOR ORGAN SHARING REGISTRY1,2,3 , 1994, Transplantation.

[7]  S. Hariharan,et al.  Risk factors for renal allograft survival from older cadaver donors. , 1998, Transplantation.

[8]  D. Rush,et al.  Sequential protocol biopsies in renal transplant patients. Clinico-pathological correlations using the Banff schema. , 1995, Transplantation.

[9]  B. F. Miller,et al.  Experiences with renal homotransplantation in the human: report of nine cases. , 1955, The Journal of clinical investigation.

[10]  R. Merion,et al.  Cyclosporine: five years' experience in cadaveric renal transplantation. , 1984, The New England journal of medicine.

[11]  L. Paul.  Chronic renal transplant loss. , 1995, Kidney international.

[12]  M. Henry,et al.  Predictors of long-term primary cadeveric renal transplant survival , 1993 .

[13]  E. Sullivan,et al.  Higher maintenance cyclosporine dose decreases the risk of graft failure in North American children: a report of the North American Pediatric Renal Transplant Cooperative Study. , 1996, Journal of the American Society of Nephrology : JASN.

[14]  M. M. Rees,et al.  Mycophenolate mofetil in cadaveric renal transplantation , 1999 .

[15]  G. Danovitch,et al.  The effect of race on access and outcome in transplantation. , 1991, The New England journal of medicine.

[16]  J. Alexander,et al.  Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival. , 1996, Clinical transplantation.

[17]  P. Kimball,et al.  Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. , 1991, Transplantation.

[18]  J. Alexander,et al.  Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era. , 1996, Clinical transplantation.

[19]  P. Nickerson,et al.  Beneficial effects of treatment of early subclinical rejection: a randomized study. , 1998, Journal of the American Society of Nephrology : JASN.

[20]  D. Dunn,et al.  Risk factors for chronic rejection in renal allograft recipients. , 1993, Transplantation.

[21]  Sollinger Hw.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .

[22]  J. Pirsch,et al.  Long-term efficacy and safety of cyclosporine in renal-transplant recipients. , 1994, The New England journal of medicine.

[23]  S. Hariharan,et al.  Effect of race on renal transplant outcome. , 1993, Clinical transplantation.

[24]  M. Mihatsch,et al.  Long-term benefits and risks of cyclosporin A (sandimmun)--an analysis at 10 years. , 1994, Transplantation proceedings.

[25]  P. Morris,et al.  Factors influencing outcome in cadaveric renal transplantation , 1994, The British journal of surgery.

[26]  R. Jindal,et al.  Chronic Rejection in Kidney Transplants , 1999, Nephron.

[27]  F. Cosio,et al.  Impact of acute rejection and early allograft function on renal allograft survival. , 1997, Transplantation.